332 related articles for article (PubMed ID: 24782313)
21. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor.
Hurt DE; Widom J; Clardy J
Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):312-23. PubMed ID: 16510978
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
Heikkilä T; Ramsey C; Davies M; Galtier C; Stead AM; Johnson AP; Fishwick CW; Boa AN; McConkey GA
J Med Chem; 2007 Jan; 50(2):186-91. PubMed ID: 17228860
[TBL] [Abstract][Full Text] [Related]
23. Tetrahydro-1H,5H-pyrazolo[1,2-a]pyrazole-1-carboxylates as inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Strašek N; Lavrenčič L; Oštrek A; Slapšak D; Grošelj U; Klemenčič M; Brodnik Žugelj H; Wagger J; Novinec M; Svete J
Bioorg Chem; 2019 Aug; 89():102982. PubMed ID: 31132601
[TBL] [Abstract][Full Text] [Related]
24. Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase.
Malmquist NA; Gujjar R; Rathod PK; Phillips MA
Biochemistry; 2008 Feb; 47(8):2466-75. PubMed ID: 18225919
[TBL] [Abstract][Full Text] [Related]
25. Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.
Kokkonda S; Deng X; White KL; El Mazouni F; White J; Shackleford DM; Katneni K; Chiu FCK; Barker H; McLaren J; Crighton E; Chen G; Angulo-Barturen I; Jimenez-Diaz MB; Ferrer S; Huertas-Valentin L; Martinez-Martinez MS; Lafuente-Monasterio MJ; Chittimalla R; Shahi SP; Wittlin S; Waterson D; Burrows JN; Matthews D; Tomchick D; Rathod PK; Palmer MJ; Charman SA; Phillips MA
J Med Chem; 2020 May; 63(9):4929-4956. PubMed ID: 32248693
[TBL] [Abstract][Full Text] [Related]
26. Understanding the structural requirements in diverse scaffolds for the inhibition of P. falciparum dihydroorotate dehydrogenase (PfDHODH) using 2D-QSAR, 3D-pharmacophore and structure-based energy- optimized pharmacophore models.
Aher RB; Roy K
Comb Chem High Throughput Screen; 2015; 18(2):217-26. PubMed ID: 25543684
[TBL] [Abstract][Full Text] [Related]
27. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Singh A; Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
[TBL] [Abstract][Full Text] [Related]
28. Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.
Silveira FF; de Souza JO; Hoelz LVB; Campos VR; Jabor VAP; Aguiar ACC; Nonato MC; Albuquerque MG; Guido RVC; Boechat N; Pinheiro LCS
Eur J Med Chem; 2021 Jan; 209():112941. PubMed ID: 33158577
[TBL] [Abstract][Full Text] [Related]
29. Gentisyl alcohol and homogentisic acid: Plasmodium falciparum dihydroorotate dehydrogenase inhibitors isolated from fungi.
Pramisandi A; Kurnia K; Chrisnayanti E; Bernawati P; Dobashi K; Mori M; Mahsunah AH; Nonaka K; Matsumoto A; Kristiningrum ; Hidayati DN; Dewi D; Prabandari EE; Amalia E; Rahmawati Y; Nurkanto A; Inaoka DK; Waluyo D; Kita K; Nozaki T; Ōmura S; Shiomi K
J Gen Appl Microbiol; 2021 Jul; 67(3):114-117. PubMed ID: 33814517
[TBL] [Abstract][Full Text] [Related]
30. Design and tests of prospective property predictions for novel antimalarial 2-aminopropylaminoquinolones.
Clark RD; Morris DN; Chinigo G; Lawless MS; Prudhomme J; Le Roch KG; Lafuente MJ; Ferrer S; Gamo FJ; Gadwood R; Woltosz WS
J Comput Aided Mol Des; 2020 Nov; 34(11):1117-1132. PubMed ID: 32833084
[TBL] [Abstract][Full Text] [Related]
31. QSAR study on the antimalarial activity of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors.
Hou X; Chen X; Zhang M; Yan A
SAR QSAR Environ Res; 2016; 27(2):101-24. PubMed ID: 26911561
[TBL] [Abstract][Full Text] [Related]
32. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model.
Booker ML; Bastos CM; Kramer ML; Barker RH; Skerlj R; Sidhu AB; Deng X; Celatka C; Cortese JF; Guerrero Bravo JE; Crespo Llado KN; Serrano AE; Angulo-Barturen I; Jiménez-Díaz MB; Viera S; Garuti H; Wittlin S; Papastogiannidis P; Lin JW; Janse CJ; Khan SM; Duraisingh M; Coleman B; Goldsmith EJ; Phillips MA; Munoz B; Wirth DF; Klinger JD; Wiegand R; Sybertz E
J Biol Chem; 2010 Oct; 285(43):33054-33064. PubMed ID: 20702404
[TBL] [Abstract][Full Text] [Related]
33. In-Silico molecular docking and simulation studies on novel chalcone and flavone hybrid derivatives with 1, 2, 3-triazole linkage as vital inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
Thillainayagam M; Malathi K; Ramaiah S
J Biomol Struct Dyn; 2018 Nov; 36(15):3993-4009. PubMed ID: 29132266
[TBL] [Abstract][Full Text] [Related]
34. Identification of inhibitors that dually target the new permeability pathway and dihydroorotate dehydrogenase in the blood stage of Plasmodium falciparum.
Dickerman BK; Elsworth B; Cobbold SA; Nie CQ; McConville MJ; Crabb BS; Gilson PR
Sci Rep; 2016 Nov; 6():37502. PubMed ID: 27874068
[TBL] [Abstract][Full Text] [Related]
35. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
[TBL] [Abstract][Full Text] [Related]
36. Structural analyses of the malaria parasite aminoacyl-tRNA synthetases provide new avenues for antimalarial drug discovery.
Chhibber-Goel J; Yogavel M; Sharma A
Protein Sci; 2021 Sep; 30(9):1793-1803. PubMed ID: 34184352
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases.
Bedingfield PT; Cowen D; Acklam P; Cunningham F; Parsons MR; McConkey GA; Fishwick CW; Johnson AP
J Med Chem; 2012 Jun; 55(12):5841-50. PubMed ID: 22621375
[TBL] [Abstract][Full Text] [Related]
38. Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation.
Sindhe KMV; Wu W; Legac J; Zhang YK; Easom EE; Cooper RA; Plattner JJ; Freund YR; DeRisi JL; Rosenthal PJ
mBio; 2020 Jan; 11(1):. PubMed ID: 31992618
[TBL] [Abstract][Full Text] [Related]
39. Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Gujjar R; El Mazouni F; White KL; White J; Creason S; Shackleford DM; Deng X; Charman WN; Bathurst I; Burrows J; Floyd DM; Matthews D; Buckner FS; Charman SA; Phillips MA; Rathod PK
J Med Chem; 2011 Jun; 54(11):3935-49. PubMed ID: 21517059
[TBL] [Abstract][Full Text] [Related]
40. Diversity-oriented synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors.
Lukens AK; Heidebrecht RW; Mulrooney C; Beaudoin JA; Comer E; Duvall JR; Fitzgerald ME; Masi D; Galinsky K; Scherer CA; Palmer M; Munoz B; Foley M; Schreiber SL; Wiegand RC; Wirth DF
J Infect Dis; 2015 Apr; 211(7):1097-103. PubMed ID: 25336726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
